The FDA and EMA approved Libtayo monotherapy (if PD-L1 expression is ≥ 50% of tumor cells) or in combination with chemotherapy (PD-L1 1-49%) as first-line therapy for adult NSCLC patients who express PD-L1 (in ≥50% tumor cells), with no EGFR, ALK or ROS1 aberrations, and who have locally advanced or metastatic NSCLC and are not candidates for definitive chemoradiation therapy. Here, ALK is linked to neoplasm.